A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Trial Profile

A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT CF
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Mar 2017 This trial has been suspended in Germany, according to European Clinical Trials Database.
    • 23 Mar 2017 This trial has been Discontinued in Germany, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top